Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

After re-staging patients, ideally with PSMA-PET, and performing a biopsy to confirm the recurrence and stratify them into risk categories, it is time to discuss local salvage treatment. Options ...

A ground-breaking treatment for cancer described by doctors as being like a ‘heat seeking missile’ has boosted survival rates and quality of life for patients with fewer side effects.

The Elekta Unity MR-LINAC system, used at Allegheny General Hospital, combines MRI imaging with radiation therapy to target cancerous cells with pinpoint precision.

It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor tissue penetration and off-target toxicity. These drawbacks can prevent complete ...

Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to prostate cancer poster session. Dr. Zachary Klaassen presented the results of a population-based analysis evaluating ...

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...

Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to ...

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

With a new treatment for prostate cancer in play, men with more aggressive forms of prostate cancer may have a more positive outlook.

Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall ...